RSS Feeds
Olfactory Status and Response to Clomiphene in Male Gonadotrophin Deficiency
- CARLOS R. HAMILTON, JR., M.D.;
- ROBERT I. HENKIN, M.D.;
- GORDON WEIR, M.D.; and
- BERNARD KLIMAN, M.D.
Abstract
Clomiphene citrate, 200 mg daily for 7 to 14 days and 50 to 100 mg daily for 4 additional weeks, produces significant increases in plasma levels of gonadotrophins and testosterone in normal males. Patients with multiple anterior pituitary hormone deficiencies or with isolated gonadotrophin deficiency and type I hyposmia (absent response to vapors at the primary olfactory area) were unresponsive to clomiphene. With clomiphene treatment two of three patients with type II hyposmia (subnormal olfactory responsiveness) and one of two patients with normal olfaction and hypogonadotrophic hypogonadism had increases of levels of plasma testosterone and plasma or urinary gonadotrophins to the normal male range. Normal spermatogenesis was demonstrated in two cases and fertility in one. Clomiphene is effective treatment for certain males with gonadotrophin deficiency.
Article and Author Information
-
▸From the Department of Medicine, Harvard Medical School, and the Endocrine Unit, Massachusetts General Hospital, Boston, Mass.; the Department of Medicine, Johns Hopkins University School of Medicine, and Johns Hopkins Hospital, Baltimore, Md.; and the Section on Neuroendocrinology, Experimental Therapeutics Branch, National Heart and Lung Institute, National Institutes of Health, Bethesda, Md.
-
Supported in part by grants AM-04501, FR-05486-08, and RR-35, U.S. Public Health Service, Washington, D.C.
-
▸Requests for reprints should be addressed to Carlos R. Hamilton, M.D., Wilford Hall U.S. Air Force Medical Center, San Antonio, Tex. 78237.
-
- Received June 26, 1972.
- Accepted September 29, 1972.
Related Clinical Content
